Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy.
EPIGET Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy.
Cardiovasc Diabetol. 2020 Nov 3;19(1):187. doi: 10.1186/s12933-020-01158-6.
Depression and cardiovascular disease (CVD) are among the most common causes of disability in high-income countries, depression being associated with a 30% increased risk of future CV events. Depression is twice as common in people with diabetes and is associated with a 60% rise in the incidence of type 2 diabetes, an independent CVD risk factor. Proprotein convertase subtilisin/kexin type 9 (PCSK9), a key regulator of low-density lipoprotein cholesterol, has been related to a large number of CV risk factors, including insulin resistance. Aim of this study was to investigate whether the presence of depression could affect PCSK9 levels in a population of obese subjects susceptible to depressive symptoms and how these changes may mediate a pre-diabetic risk.
In 389 obese individuals, the Beck Depression Inventory (BDI-II) was significantly associated with PCSK9 levels. For every one-unit increment in BDI-II score, PCSK9 rose by 1.85 ng/mL. Depression was associated also with the HOMA-IR (homeostatic model assessment index of insulin resistance), 11% of this effect operating indirectly via PCSK9.
This study indicates a possible mechanism linking depression and insulin resistance, a well-known CV risk factor, providing evidence for a significant role of PCSK9.
在高收入国家,抑郁症和心血管疾病(CVD)是导致残疾的最常见原因之一,抑郁症与未来心血管事件的风险增加 30%有关。糖尿病患者中抑郁症的发病率是普通人群的两倍,与 2 型糖尿病发病率增加 60%有关,而 2 型糖尿病是独立的心血管危险因素。脯氨酸羧肽酶/激肽释放酶 9(PCSK9)是一种调节低密度脂蛋白胆固醇的关键酶,与许多心血管危险因素有关,包括胰岛素抵抗。本研究旨在探讨抑郁症状候群肥胖人群中抑郁的存在是否会影响 PCSK9 水平,以及这些变化如何调节糖尿病前期风险。
在 389 名肥胖个体中,贝克抑郁量表(BDI-II)与 PCSK9 水平显著相关。BDI-II 评分每增加一个单位,PCSK9 升高 1.85ng/ml。抑郁也与 HOMA-IR(胰岛素抵抗的稳态模型评估指数)有关,这种影响有 11%是通过 PCSK9 间接作用的。
本研究表明,抑郁和胰岛素抵抗之间可能存在一种联系,而胰岛素抵抗是众所周知的心血管危险因素,这为 PCSK9 发挥重要作用提供了证据。